Concomitant use of immunosuppressive therapy with tumor necrosis factor (TNF) antagonists in inflammatory bowel disease

Parambir S. Dulai, Corey A. Siegel*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The treatment paradigm of ulcerative colitis (UC) and Crohn’s disease (CD) has shifted considerably over the past decade. Despite the advancements in our understanding of treatment monitoring and optimization, one of the key questions that continues to be debated is the optimal approach to using concomitant immunosuppressive agents. Well-designed randomized controlled trials have suggested that a clear treatment benefit exists; however, the external validity and applicability of these findings to the general population, and the personalization of treatment decisions based on individual factors and safety, remain to be clarified. In this review, we will discuss the evidence available for treatment efficacy, the impact safety may have on treatment decisions, and opportunities available to optimize the potential application and personalization of concomitant immunosuppressive therapy.

Original languageEnglish (US)
Title of host publicationTreatment of Inflammatory Bowel Disease with Biologics
PublisherSpringer International Publishing
Pages101-112
Number of pages12
ISBN (Electronic)9783319602769
ISBN (Print)9783319602752
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Keywords

  • Combination therapy
  • Immunosuppressive agents
  • Lymphoma
  • Monotherapy
  • TNF-antagonist

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Concomitant use of immunosuppressive therapy with tumor necrosis factor (TNF) antagonists in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this